{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"56.5","upperLimit":"91.3","value":"73.9"},{"groupId":"OG001","lowerLimit":"30.2","upperLimit":"63.6","value":"46.9"},{"groupId":"OG002","lowerLimit":"14.1","upperLimit":"47.5","value":"30.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"32"},{"groupId":"OG002","value":"26"}],"units":"Participants"}],"description":"Progression was defined as 25% increase in the size of any measurable lesion; the appearance of a new lesion; or the conversion of negative cerebrospinal fluid (CSF) cytology to positive. Defined as the time interval from date on treatment until the date of first progression, medulloblastoma-related death or date of last contact for patients who have not experienced an event. All eligible medulloblastoma patients who received any methotrexate are included in this analysis.","dispersionType":"95% Confidence Interval","groups":[{"description":"Medulloblastoma patients \\<3 years of age; histological diagnosis of desmoplastic nodular (DN)/medulloblastoma with extensive nodularity (MBEN); no evidence of metastatic disease (M0); and a surgical gross total resection (GTR) or near total resection (NTR) defined as residual tumor or imaging abnormality (not definite for residual tumor) with a size of less than 1 cm\\^2 on post-op computed tomography (CT) or magnetic resonance imaging (MRI) \\[R0\\])","id":"OG000","title":"Low-Risk Group"},{"description":"Medulloblastoma patients \\<3 years of age, M0, and either R0 resection with any other medullo histology other than DN/MBEN (i.e., classic or large cell anaplastic (LCA)), or with a subtotal resection (with a residual tumor or imaging abnormality with a size of \\>1 cm\\^2 on post-op imaging (R+), and DN/MBEN). Children 3-5 years of age were also included in this group High Risk","id":"OG001","title":"Intermediate-Risk Group"},{"description":"Medulloblastoma patients \\<3 years of age with evidence of metastatic disease","id":"OG002","title":"High-Risk Group"}],"paramType":"NUMBER","populationDescription":"All eligible medulloblastoma patients started methotrexate and were included (n=81). PFS estimates are reported by risk group.","reportingStatus":"POSTED","timeFrame":"From date on treatment until date of first progression or relapse or disease related death or date of last contact, estimated at 1 year after treatment","title":"Percent Probability of Progression-free Survival (PFS) for Medulloblastoma Patients","type":"PRIMARY","unitOfMeasure":"Percent Probability"}